Progress of treatment-free remission in chronic myeloid leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 253-256, 2022.
Article
in Zh
| WPRIM
| ID: wpr-929768
Responsible library:
WPRO
ABSTRACT
The application of tyrosine kinase inhibitor (TKI), a target therapy of chronic myeloid leukemia (CML), has greatly improved the prognosis of patients with CML. However, uninterrupted treatment with TKI affects the quality of life and aggravates the economic burden of patients. Achieving treatment-free remission (TFR) has become the current research direction of CML treatment. This paper reviews the relevant foreign literature on the discontinuation of TKI in recent years.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of Leukemia & Lymphoma
Year:
2022
Type:
Article